JAVIER
ESCANED BARBOSA
Profesor asociado de Ciencias de la Salud
![Foto de JAVIER](/img/uploaded/B1C208A8E1820F13282153D4BA39B96E.jpg)
![Foto de Icahn School of Medicine at Mount Sinai](/img/noimage_org.png)
Icahn School of Medicine at Mount Sinai
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Icahn School of Medicine at Mount Sinai (27)
2024
-
Correction to: Optical coherence tomography in coronary atherosclerosis assessment and intervention (Nature Reviews Cardiology, (2022), 19, 10, (684-703), 10.1038/s41569-022-00687-9)
Nature Reviews Cardiology
-
Global Consensus Recommendations on Improving the Safety of Chronic Total Occlusion Interventions
Heart Lung and Circulation, Vol. 33, Núm. 7, pp. 915-931
-
Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial
American Heart Journal, Vol. 272, pp. 11-22
2023
-
Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT
International Journal of Cardiology, Vol. 383, pp. 24-32
-
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions
Journal of the American College of Cardiology, Vol. 82, Núm. 8, pp. 687-700
-
Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial
American Journal of Cardiology, Vol. 208, pp. 16-24
-
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention
JACC: Cardiovascular Interventions, Vol. 16, Núm. 20, pp. 2514-2524
-
Optical coherence tomography and coronary revascularization: from indication to procedural optimization
Trends in Cardiovascular Medicine, Vol. 33, Núm. 2, pp. 92-106
-
The year in cardiovascular medicine 2021: interventional cardiology
Cardiologia Hungarica, Vol. 53, Núm. 1, pp. 5-14
-
Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial
European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 9, Núm. 4, pp. 328-336
2022
-
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index
JACC: Cardiovascular Interventions, Vol. 15, Núm. 19, pp. 1948-1960
-
Optical coherence tomography in coronary atherosclerosis assessment and intervention
Nature Reviews Cardiology, Vol. 19, Núm. 10, pp. 684-703
-
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 17, Núm. 16, pp. 1330-1339
-
The year in cardiovascular medicine 2021: interventional cardiology
European heart journal, Vol. 43, Núm. 5, pp. 377-386
-
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy
JACC: Cardiovascular Interventions, Vol. 15, Núm. 3, pp. 282-293
-
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD
European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 7, pp. 707-716
-
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 18, Núm. 11, pp. e897-e909
2021
-
Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial
The Lancet, Vol. 398, Núm. 10317, pp. 2149-2159
-
Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review
Journal of the American College of Cardiology, Vol. 78, Núm. 8, pp. 840-853
-
Sex Differences among Patients with High Risk Receiving Ticagrelor with or without Aspirin after Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial
JAMA Cardiology, Vol. 6, Núm. 9, pp. 1032-1041